CCL17 and psoriasis: In this study, we found that the expression of Th2‐related TARC, DEFB2, and IL‐13 was significantly increased in the serum of patients with moderate‐to‐severe psoriasis and was not significantly decreased after secukinumab treatment, especially DEFB2, whose serum expression level remained significantly higher than normal after secukinumab treatment.